Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

Journal of Clinical Oncology

Volumn 26, Issue 29, 2008, Pages 4784-4790

  Chanan Khan, Asher ^a   Sonneveld, Pieter ^a   Schuster, Michael W ^a   Stadtmauer, Edward A ^a   Facon, Thierry ^a   Harousseau, Jean Luc ^a   Ben Yehuda, Dina ^a   Lonial, Sagar ^a   Goldschmidt, Hartmut ^a   Reece, Donna ^a   Neuwirth, Rachel ^a   Anderson, Kenneth C ^a   Richardson, Paul G ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; ESOPHAGUS CANDIDIASIS; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX DERMATITIS; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOUTH INFECTION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYCOSIS; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PULMONARY CANDIDIASIS; RISK FACTOR; SEPTICEMIA; THRUSH; VIRUS REACTIVATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HERPES ZOSTER; HUMANS; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; VIRUS ACTIVATION;

EID: 54249089458     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.9641     Document Type: Article

References (26)

1. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001
2. Richardson PG, Hideshima T, Anderson KC: Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10:361-369, 2003
3. Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136-1144, 2003
4. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, et al: Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107:3575-3583, 2006
5. Nencioni A, Schwarzenberg K, Brauer KM, et al: Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 108: 551-558, 2006
6. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al: Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 101:8120-8125, 2004
7. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
8. Richardson PG, Sonneveld P, Schuster M, et al: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 110:3557-3560, 2007
9. Hambleton S, Gershon AA: Preventing varicella-zoster disease. Clin Microbiol Rev 18:70-80, 2005
10. Morison WL: Herpes simplex and herpes zoster in neoplasia. Lancet 1:1293, 1974
11. Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165-172, 2004
12. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
13. Tong Y, Qian J, Li Y, et al: The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol 82:403-404, 2007
14. Wu KL, van Wieringen W, Vellenga E, et al: Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica 90:996-997, 2005
15. Kroger N, Zabelina T, Ayuk F, et al: Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 34:770-775, 2006
16. Lionakis MS, Kontoyiannis DP: Glucocorticoids and invasive fungal infections. Lancet 362: 1828-1838, 2003
17. Gilden DH, Cohrs RJ, Mahalingam R: Clinical and molecular pathogenesis of varicella virus infection. Viral Immunol 16:243-258, 2003
18. Cohen JI, Brunell PA, Straus SE, et al: Recent advances in varicella-zoster virus infection. Ann Intern Med 130:922-932, 1999
19. Kay NE, Leong T, Bone N, et al: T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br J Haematol 100:459-463, 1998
20. Schutt P, Brandhorst D, Stellberg W, et al: Immune parameters in multiple myeloma patients: Influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 47:1570-1582, 2006
21. Uy GL, Peles S, Fisher NM, et al.: Bortezomib prior to autologous transplant in multiple myeloma: Effects on mobilization, engraftment, and markers of immune function. Biol Blood Marrow Transplant 12:116, 2006 (abstr 331)
22. Mele G, Pinna S, Quarta A, et al: Increased incidence of herpes zoster in relapsed multiple myeloma patients receiving bortezomib: Single institution experience. Haematologica 90:432, 2005 (suppl 2, abstr 119)
23. Nencioni A, Garuti A, Schwarzenberg K, et al: Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 36:681-689, 2006
24. Kumar S, Witzig TE, Rajkumar SV: Thalidomide as an anti-cancer agent. J Cell Mol Med 6:160-174, 2002
25. Pour LP, Hajek R, Adam Z, et al: Exanthema and herpes zoster infection during Velcade use: Incidence, treatment and prophylaxis. Haematologica 91:443, 2006 (abstr 1227)
26. Mateos MV, Hernandez JM, Hernandez MT, et al: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 108:2165-2172, 2006